News

There are promising developments in the pipeline for patients with treatment-resistant depression.

Managed Healthcare Executive conducted its first-ever managed care pharmacy survey during the second quarter of 2016 in partnership with Access Market Intelligence. Here’s a look at some of the key findings, with experts weighing in on the results.

Rising drug costs are a big problem for all healthcare systems in the U.S. Here’s how three hospitals are addressing the problem.

After protests by patients, parents and Congressional representatives, Mylan said it would offer discounts on its epinephrine EpiPen Auto-Injector treatment to stop allergic reactions.

FDA recently granted Breakthrough Therapy Designation for esketamine (Janssen Research & Development), an investigational medication to treat major depressive disorder with imminent risk for suicide.

As health plans work to develop and price products for the 2017 open-enrollment cycle-beginning November 1, 2016, it looks like some premiums are set to rise substantially.

Expert: Expectations are high that biosimilars can control overall biologic cost growth.

CMS just released the first Comprehensive Care for Joint Replacement (CJR) data feed. Find out what the preliminary results show.

Here’s what to expect from Blue Shield of California’s four-day closure over Obamacare losses.

PCSK9 inhibitors such as alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) are priced too high to benefit the US healthcare system, according to a new study.

As Aetna bows out of health insurance exchanges, more questions about viability are cropping up. Find out which other plans are exiting the health insurance exchanges.

FDA recently approved granisetron (Sustol, Heron Therapeutics) extended-release injection to prevent nausea and vomiting associated with repeat courses of chemotherapy.

Here is a list of critical concepts physician leaders must master-and instill in others-in order to thrive.

Outsourcing means giving up a vital part of what you do as a business, so it’s a strategy that should be approached carefully. On the other hand, not outsourcing could also threaten the success of your organization.

The presidential hopefuls have very different views about the ACA. Expect three healthcare things that will stay the same even after Obama leaves office.

In an era when legislators, pharmacy benefit managers and others continue to protest the high cost of hepatitis C drugs, new drugs to treat the disease are welcomed. FDA recently approved ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets (Viekira XR, AbbVie) to treat patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection, including those with cirrhosis. AbbVie already markets Viekira Pak, which competes with Harvoni and Sovaldi (Gilead Sciences).

Executives need to ask themselves four key questions to mitigate the negative impact of rising drug costs.

A survey from Vizient of CMS previews reports from member hospitals. Here are the findings.

To generate leads, convert prospects and keep members engaged, health plans must employ a high-touch, multi-channel healthcare marketing strategy which will be much more effective and enroll members who may have not otherwise done so.

Merck’s Wall Street value is climbing after its cancer drug pembrolizumab (Keytruda) received yet another approval from FDA.

New NCCN guidelines include new technology as an option for patients’ annual screening.

Many healthcare organizations lack the necessary governance principles, guidelines, and processes necessary for success in today’s technology-dependent environment.

For healthcare organizations, now is the time to help address Zika fears by utilizing digital tools.

What has you counting sheep at night? Answers from your peers may surprise you.

When Express Scripts and CVS Health announced their 2017 formularies on August 1, a common theme emerged among the healthcare giants: several blockbuster drugs will be removed from both companies’ formularies and lower-cost options such as biosimilars are being embraced.

Systematic review provides comprehensive first look at TNF-alpha biosimilar treatments.

Doctors in these states are now eligible for CPC+. Experts share how to prepare.

Below are some perspectives on what these complaints mean for the parties’ chances and for consolidation in healthcare more generally.